Juno Therapeutics Inc (NASDAQ:JUNO) has the appointed Cindy Elkins as its Chief Information Officer (CIO). Elkins will be working directly under Hans Bishop, the company’s President and CEO. Juno Therapeutics Inc is a biopharmaceutical company that specializes in the development of innovative cellular immunotherapies used in the treatment of cancer.
While commenting on the appointment, Mr. Bishop said Cindy has a lot of experience in the industry and has a track record of raiding the impact of communication technology in the biotech industry. He added that Cindy is known for advancing innovation as well as delivering well developed technologies which support the discovery and development of breakthrough therapies. He added that her passion, talent and experience, will help the company in advancing its goal of bringing better medicine to patients.
Before his appointment, Ms. Elkins served as Vice President, IT for the Americas at Genentech. At Genentech, she led the integration of the US commercial technology after Genentech was acquired by Roche. Through her leadership, Genentech pioneered the implementation of several important technology platforms at scale. In addition, she had developed teams which consistently offered exceptional user experience to more than 44,000 people. Before her tenure at Genentech she served as the Vice President and General Manager of Ariba, an information technology and software technology services company, where she assisted in creating the largest web-based trading community globally.
While acknowledging her appointment, Cindy said she is very happy to join Juno adding that the company is in line with her passion for an accountable, vibrant and high-performing company which seeks to innovate at large scale. She added that she is proud to be part of the mission to change the way manner in which cancer and other ailments are treated as well as provide the infrastructure that will allow the company’s employees to work at optimum. Cindy is a member Weight Watchers Board of Directors. He has an MBA from Santa Clara University. She has BS in Applied Mathematics from UCLA.
Juno Therapeutics is developing a fully integrated biopharmaceutical firm mainly focused on developing advanced and innovative cellular immunotherapies used in the treatment of cancer.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of USmarketsDaily.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: